Workflow
瑞康医药(002589) - 2014年5月16日投资者关系活动记录表
RealcanRealcan(SZ:002589)2022-12-08 06:46

Group 1: Company Development and Revenue Growth - In 2013, the company's basic drug distribution revenue reached 539 million CNY, a year-on-year increase of 46%. Future growth is expected with the expansion of basic drugs and new bidding processes [2] - The medical device distribution business, initiated in 2012, generated 236 million CNY in 2013, marking a significant year-on-year growth of 719.70%. The company plans to invest 135 million CNY from its private placement into this sector, anticipating further expansion through both organic growth and external acquisitions [2] - The vaccine business launched in 2013 is expected to become a new growth point for the company's revenue and profits [2] Group 2: Coverage and Market Position - The company has a strong direct coverage capability, achieving a 98% coverage rate for large hospitals in the province, 100% for tertiary hospitals, and 95% for grassroots medical institutions. This aligns with national healthcare reform policies aimed at reducing distribution links [3] - The number of upstream suppliers increased from 1,380 in 2010 to 2,147 in 2013, enhancing the company's upstream distribution rights and facilitating the expansion of downstream hospital clients [3] - The high demand for pharmaceuticals from quality hospital clients ensures secure payment and strengthens negotiations with upstream suppliers, promoting mutual resource development [3]